Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
William G. Wierda(The University of Texas MD Anderson Cancer Center), Paolo Ghia(Vita-Salute San Raffaele University), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Deepa Jagadeesh(University of Massachusetts Chan Medical School), Jennifer A. Woyach(The Ohio State University), Bastien Nguyen(Eli Lilly (United States)), Catherine C. Coombs(Memorial Sloan Kettering Cancer Center), Talha Munir(Leeds Teaching Hospitals NHS Trust), David Lewis(Derriford Hospital), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), Donald E. Tsai(University of Pennsylvania), Koji Izutsu(Tokyo National Hospital), Binoj C. Nair(The University of Texas Health Science Center at San Antonio), Constantine S. Tam(The Royal Melbourne Hospital), Manish Patel(The Open University), Matthew McKinney(Duke Cancer Institute), Lindsey E. Roeker(Memorial Sloan Kettering Cancer Center), Toby A. Eyre(Churchill Hospital), Samuel McNeely(Eli Lilly (United States)), Joanna Rhodes(Roswell Park Comprehensive Cancer Center), Paolo Abada(University of California, San Diego), Chan Y. Cheah(The University of Western Australia), Philip A. Thompson(The University of Texas MD Anderson Cancer Center), John F. Seymour(The Royal Melbourne Hospital), Caleb Ho(Memorial Sloan Kettering Cancer Center), Alvaro J. Alencar(University of Miami), Nirav N. Shah(Medical College of Wisconsin), Hui Liu(Sichuan University), Shuo Ma(Northwestern University), Wojciech Jurczak(The Maria Sklodowska-Curie National Research Institute of Oncology), Yucai Wang(Mayo Clinic), Amy S. Ruppert(The Ohio State University), Narasimha Marella(Loxo Oncology at Lilly (United States)), Chunxiao Wang(Eli Lilly (United States)), Marc Hoffmann(The University of Kansas Cancer Center)
Cited by 37
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k